- Home
- ELF vs NAMS Comparison
ELF vs NAMS Comparison
Compare ELF & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELF | NAMS |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.0B |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELF | NAMS |
|---|---|---|
| Price | $85.81 | $36.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 10 |
| Target Price | ★ $127.00 | $46.40 |
| AVG Volume (30 Days) | ★ 1.6M | 856.3K |
| Earning Date | 02-05-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $1,385,640,000.00 | $35,243,000.00 |
| Revenue This Year | $20.59 | N/A |
| Revenue Next Year | $16.79 | N/A |
| P/E Ratio | $58.71 | ★ N/A |
| Revenue Growth | ★ 13.80 | 4.91 |
| 52 Week Low | $49.40 | $14.06 |
| 52 Week High | $150.99 | $42.00 |
Technical Indicators
Market Signals| Indicator | ELF | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 59.61 | 52.19 |
| Support Level | $75.73 | $32.67 |
| Resistance Level | $80.87 | $35.70 |
| Average True Range (ATR) | 3.45 | 1.47 |
| MACD | 1.22 | 0.09 |
| Stochastic Oscillator | 82.61 | 77.85 |
Price Performance
Historical ComparisonAbout ELF e.l.f. Beauty Inc.
e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan, and cruelty-free cosmetics and skin care products. The Company's mission is to make beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women, which include eyeliner, mascara, false eyelashes, lipstick, foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.